Plaquenil and Zosyn Drug Interaction Assessment

Key Safety Considerations

• Hydroxychloroquine is a known cause of QT interval prolongation and torsade de pointes, though this occurs rarely in clinical practice 1, 2
• The American College of Cardiology recommends withholding hydroxychloroquine in patients with baseline QTc ≥500 ms or known congenital long-QT syndrome 1, 3
• Monitor cardiac rhythm and QTc interval during therapy, and discontinue if QTc exceeds 500 ms 1, 3
• Correct hypomagnesemia and hypokalemia before and during hydroxychloroquine therapy 1, 2

Clinical Management Algorithm

• Obtain baseline ECG to measure QTc interval 1, 3
• Review patient's medication list for other QT-prolonging agents 1
• If QTc <500 ms and electrolytes normal: Both medications can be safely administered together 1
• Monitor QTc interval periodically, especially in critically ill patients 1, 3

High-Risk Situations Requiring Enhanced Monitoring

• Advanced age and female sex increase arrhythmia risk with QT-prolonging drugs 1, 2
• Critically ill patients often have fever, inflammatory states, and electrolyte disturbances that compound arrhythmia risk 1, 4

Common Pitfalls to Avoid

• Do not continue hydroxychloroquine if QTc exceeds 500 ms, as this threshold represents unacceptable arrhythmia risk 1, 3
• Do not overlook drug-drug interactions with other QT-prolonging medications that may be part of the patient's regimen 1

Hydroxychloroquine-Induced Hypokalemia

Risk Factors and Clinical Context

• The American Society of Clinical Oncology and other guideline societies recommend caution when hydroxychloroquine is combined with other medications that can cause electrolyte disturbances, such as corticosteroids, cisplatin, and other chemotherapeutic agents, as this increases the risk of hypokalemia 5, 6
• Hypokalemia (potassium <3.4 mmol/L) is a modifiable risk factor that increases the risk of drug-induced QT prolongation and torsades de pointes when using hydroxychloroquine, according to the American Heart Association 7, 8

Monitoring and Management

• The National Comprehensive Cancer Network recommends monitoring serum potassium levels in patients taking hydroxychloroquine, especially when adding other medications that may affect potassium levels, as this can help prevent hypokalemia 5
• Patients with risk factors for QT prolongation, such as hypokalemia, should be closely monitored, as the combination of hypokalemia and QT prolongation significantly increases the risk of torsades de pointes and sudden cardiac death, according to the American College of Cardiology 5, 7